What is Kazia Therapeutics Ltd ADR's share price today?
Kazia Therapeutics Ltd ADR (KZIA) share price today is $7.13 as of November 7, 2026 at 2:29 AM IST. The stock touched a day high of $7.51 and a day low of $6.98.What exchange does Kazia Therapeutics Ltd ADR stock trade on, and under what ticker symbol?
Kazia Therapeutics Ltd ADR stock trades on NASDAQ under the ticker symbol KZIA.What is Kazia Therapeutics Ltd ADR's market capitalization?
Kazia Therapeutics Ltd ADR's market capitalization is $92.32M as of November 7, 2026 at 2:29 AM IST.What is Kazia Therapeutics Ltd ADR's price-to-earnings (P/E) ratio?
Kazia Therapeutics Ltd ADR's price-to-earnings (P/E) ratio is N/A as of November 6, 2026.What is Kazia Therapeutics Ltd ADR's price-to-book (P/B) ratio?
Kazia Therapeutics Ltd ADR's price-to-book (P/B) ratio is 3.81 as of November 6, 2026.Can Indian investors buy Kazia Therapeutics Ltd ADR shares?
Yes, You can buy Kazia Therapeutics Ltd ADR shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in Kazia Therapeutics Ltd ADR shares from India?
Indian investors can buy Kazia Therapeutics Ltd ADR shares in three steps: 1. Search Kazia Therapeutics Ltd ADR on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from Kazia Therapeutics Ltd ADR shares for Indian investors?
Since Kazia Therapeutics Ltd ADR trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in Kazia Therapeutics Ltd ADR shares via Tickertape?
Indian investors can start investing in Kazia Therapeutics Ltd ADR (KZIA) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.4023 shares at the current price of $7.13.
$
₹
$7.131.87% (+0.13)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
Key Metrics
Key Metrics
PE TTM
PE TTM
Close price divided by the earnings per share for the trailing twelve months
—
PB
PB
Close price divided by the book value per share at the end of the most recent quarter
3.81
EPS TTM
EPS TTM
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
$-6.85
PEG Ratio
PEG Ratio
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
1.01
Profit Margin
Profit Margin
Net profit divided by the total revenue for the most recent financial year
0%
Dividend Yield
Dividend Yield
Annual dividend per share for the trailing twelve months divided by the close price
—
Based on 8 analysts reports
Buy8 analysts
Hold0 analyst
Sell0 analyst
Price Upside
+308.13%
Earnings Growth
—
Rev. Growth
+1919.33%
Company Profile
Company Profile
ABBV
P/E Ratio
50.65
50.65
1Y Return
31.59%
31.59%
Buy Reco %
79.31
79.31
AMGN
P/E Ratio
27.73
27.73
1Y Return
46.88%
46.88%
Buy Reco %
35.29
35.29
P/E Ratio
—
—
1Y Return
35.24%
35.24%
Buy Reco %
78.57
78.57
P/E Ratio
35.33
35.33
1Y Return
31.43%
31.43%
Buy Reco %
81.25
81.25
MRNA
P/E Ratio
—
—
1Y Return
944.75%
944.75%
Buy Reco %
17.39
17.39
Forecast
Forecast
Price
Revenue
Earnings
Price Forecast
Price Forecast
2026
Current$7.18Baseline
Analyst Target - 1 year
Target$29.3+308.13%
All values in $
2026
Current$7.18Baseline
Analyst Target - 1 year
Target$29.3+308.13%
All values in $
Revenue Forecast
Revenue Forecast
Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.
The next fiscal year's mean estimate implies 1919.33% growth, versus a trailing 3-year CAGR of 61.34%.
2025
Current$0.04Baseline
Forecast for Jun 2026
High$2.8+6566.67%
Average$0.84+1919.33%
Low$0-100%
All values in $ Million
2025
Current$0.04Baseline
Forecast for Jun 2026
High$2.8+6566.67%
Average$0.84+1919.33%
Low$0-100%
All values in $ Million
Financials
Financials
Income
Balance Sheet
Cash Flow
Quarterly Normal View
Q4 2024
Q2 2025
Q3 2025
Q4 2025
Revenue
Net Income
| Financial Year | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | - | 0 | 0 | - | 2.48 | 0.02 | - | 0.01 | - |
Gross Profit | 0 | - | 0 | 0 | - | 2.48 | 0.02 | - | 0.01 | - |
| Net Income | -3.43 | - | -6.87 | -8.82 | - | -17.95 | -10.45 | - | -9.95 | -12.32 |
| Net Profit Margin | -1237257.55% | - | -687897.3% | -176470260% | - | -723.68% | -46899.10% | - | -50487.23% | - |
Peers
Peers & Comparison
Peers & Comparison
Comparing 2 stocks from
HealthcareBiotechnology
HealthcareBiotechnology
Valuation
Returns
Forecast
Compare valuation on Screener| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| Kazia Therapeutics Ltd ADR | - | 3.81 | 1.01 |
| AbbVie Inc | 50.65 | 50.45 | 0.58 |
| Amgen Inc | 27.73 | 21.33 | 2.75 |
Price Comparison
Price Comparison
Compare KZIA with any stock or ETFCompare KZIA with any stock or ETF
Comparing from
KZIA
ABBV
AMGN
The 12-month consensus target implies 308.13% growth, versus a trailing 3-year CAGR of -36.99%.